Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: May 13, 2010

Premium

Title: Treating Cancer with Viral Nucleic Acid

Application Number: 20100111873

Filed: Feb. 20, 2008 PCT Filed: Feb. 20, 2008

Lead Inventor: Stephen Russell, Mayo Clinic College of Medicine

The invention, the patent application's abstract states, comprises "methods and materials related to the use of nucleic acid coding for viruses to reduce the number of viable cancer cells within a mammal. For example, methods for using infectious nucleic acid to treat cancer, engineered viral nucleic acid, methods for making engineered viral nucleic acid, methods for identifying infectious nucleic acid for treating cancer, methods and materials for controlling virus-mediated cell lysis, and methods and materials for assessing the control of virus-mediated cell lysis are provided."

The application specifically claims the use of microRNAs to treat cancer.


Title: Processes and Compositions for Liposomal and Efficient Delivery of Gene-Silencing Therapeutics

Application Number: 20100112042

Filed: Oct. 16, 2009

Lead Inventor: Barry Polisky, MDRNA

The patent application, its abstract states, claims "processes and compositions for liposomal delivery of [therapeutics] prepared by contacting an aqueous solution of an active agent with a solution of liposome-forming components containing one or more DiLA2 amino acid compounds or lipids in organic solvent to form an impinging stream.

"A protocol including flow rates, pH, and an incubation period are used to control formation of liposomal components for therapeutic applications," the abstract notes. "The impinging stream may be collected and incubated to prepare a liposomal formulation, which encapsulates the active agent. The composition can be quenched with buffer and filtered by tangential flow and diafiltration and other means for finishing as a pharmaceutical composition."

The application also claims "an efficiency for delivering a drug cargo. … Compositions can include a liposome containing one or more carrier particles, each carrier particle having an active agent and a peptide, wherein the ratio of the mass of the peptide plus the mass of the liposome to the mass of the active agent is less than about 15."


Title: Short Hairpin RNAs for Inhibition of Gene Expression

Application Number: 20100112686

Filed: Oct. 14, 2009

Lead Inventor: Qing Ge, Somagenics

The patent application, its abstract states, claims "methods, compositions, and kits that include small hairpin RNA useful for inhibition of gene expression, such as viral-mediated gene expression."


Title: Nucleic Acid Compounds for Inhibiting ERBB Family Gene Expression and Uses Thereof

Application Number: 20100112687

Filed: Feb. 28, 2008 PCT Filed: Feb. 28, 2008

Lead Inventor: Steven Quay, MDRNA

The invention, the patent application's abstract states, comprises "meroduplex ribonucleic acid molecules capable of decreasing or silencing one or more ERBB family gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to one or more ERBB family mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine and optionally other modifications or combinations thereof.

"Also provided are methods of decreasing expression of one or more ERBB family gene in a cell or in a subject to treat one or more ERBB family-related disease," it adds.


Title: Small Interfering RNA Target Site-Blocking Oligos and Uses Thereof

Application Number: 20100113284

Filed: April 3, 2009

Lead Inventor: Alexander Aristarkhov, Exiqon

The invention "relates to nucleic acids designed to prevent the binding of single strand RNA in protein complexes originating from small interfering RNA or small hairpin RNA, and uses thereof," the patent application's abstract states.


Title: siRNA Targeting Connective Tissue Growth Factor

Application Number: 20100113306

Filed: Dec. 23, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CTGF."


Title: siRNA Targeting Vascular Endothelial Growth Factor

Application Number: 20100113307

Filed: Dec. 15, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," according to the patent application's abstract. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to VEGF."


Title: Method of Treating an Inflammatory Disease by Double-Stranded Ribonucleic Acid

Application Number: 20100113332

Filed: Sept. 27, 2005 PCT Filed: Sept. 27, 2005

Lead Inventor: Lishan Chen, Nastech Pharmaceutical (MDRNA)

The patent application, its abstract states, claims the "use of a formulation comprising double-stranded ribonucleic acid in the manufacture of a medicament for treating an inflammatory disease in a mammal and inhibiting production of tumor necrosis factor-alpha in the mammal."


Title: Therapeutic Compositions Comprising an RNAi Agent and a Neurotrophic Factor and Methods of Use Thereof

Application Number: 20100113351

Filed: Oct. 16, 2009

Lead Inventor: Eric Neal Burright, Medtronic

"The invention provides novel combination therapies for treating Huntington's disease which comprise BDNF or suitable fragments thereof and agents capable of causing inhibition of a gene responsible for the neurodegenerative disease," the patent application's abstract states. "The invention provides nucleic acid sequences, methods, and systems suitable for applications of these combination therapies."


Title: Compounds and Methods

Application Number: 20100113558

Filed: Oct. 1, 2007 PCT Filed: Oct. 1, 2007

Lead Inventor: Marianne Farnebo, Aprea

The patent application, its abstract states, claims a "small nucleic acid molecule that down-regulates expression of Wrap53 gene via RNA interference.

"At least one strand of said small nucleic acid molecule is about 15 to about 30 nucleotides in length and … at least one strand of said small nucleic acid molecule comprises a nucleotide sequence having sufficient complementarity to an RNA of [the] Wrap53 gene," it adds. The application also claims the use of the RNAi molecule as a medicament.


Title: Compositions and Methods for Treating Hematopoietic Malignancies

Application Number: 20100113560

Filed: Jan. 25, 2008 PCT Filed: Jan. 25, 2008

Lead Inventor: Judy Lieberman, Harvard Medical School (Rosetta Genomics)

The patent applications, its abstract states, claims "compositions and methods for the prevention and treatment of hematopoietic malignancies. The compositions are miRNAs and associated nucleic acids."


Title: microRNA Molecules

Application Number: 20100113561

Filed: Aug. 31, 2009

Lead Inventor: Thomas Tuschl, Rockefeller University (Max Planck Institute)

"In Caenorhabditis elegans, lin-4 and let-7 encode 22- and 21-nucleotide RNAs, respectively, that function as key regulators of developmental timing," the patent application's abstract states. "Because the appearance of these short RNAs is regulated during development, they are also referred to as small temporal RNAs. We show that many more 21- and 22-[nucleotide long] expressed RNAs, termed microRNAs, exist in invertebrates and vertebrates, and that some of these novel RNAs, similar to let-7 stRAN, are also highly conserved. This suggests that sequence-specific post-transcriptional regulatory mechanisms mediated by small RNAs are more general than previously appreciated."


Title: Therapeutic Targets and Molecules

Application Number: 20100113562

Filed: March 26, 2008 PCT Filed: March 26, 2008

Lead Inventor: Paul Stephen Foster, University of Newcastle

"The invention provides methods and compositions for treating or preventing inflammation or an inflammatory condition in a subject, comprising administering to the subject an effective amount of at least one antagonist of one or more miRNA up-regulated in inflammatory disease conditions and response to allergen challenge," the patent application's abstract states. "The invention also provides methods for diagnosing inflammatory conditions based on miRNA expression profile signatures."


Title: RNA Interference-Mediated Inhibition of Interleukin and Interleukin Receptor Gene Expression Using Short Interfering Nucleic Acid

Application Number: 20100113564

Filed: Jan. 6, 2010

Lead Inventor: James McSwiggen, Merck

"This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid molecules," according to the patent application's abstract. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin receptor gene expression and/or activity by RNA interference using small nucleic acid molecules … and methods used to modulate the expression of interleukin and/or interleukin receptor genes."


Title: Isolated Nucleic Acid Molecules Corresponding to microRNA-145 and Their Use in Treating Colon Cancer

Application Number: 20100113577

Filed: April 7, 2008 PCT Filed: April 7, 2008

Lead Inventor: Bin Shi, Merck

The patent application, its abstract states, claims "isolated nucleic acid molecules corresponding to miR-145 that are useful in treating colon cancer. The disclosed miR-145 nucleic acids specifically bind the 3' UTR within endogenous IRS-I such as to suppress or inhibit colon cell proliferation."


Title: siRNA Targeting Myeloid Differentiation Primary Response Gene 88

Application Number: 20100113760

Filed: Dec. 8, 2009

Lead Inventor:
Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MYD88."


Title: siRNA Targeting Beta Secretase

Application Number: 20100113761

Filed: Dec. 11, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," according to the patent application's abstract. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for BACE."

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.